Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
456 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2016, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape. Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation and chemotherapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 27, 24, 24, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 5, 8 and 3 molecules, respectively.Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology). - The pipeline guide reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 6 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview 7 Therapeutics Development 8 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Development by Companies 10 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Investigation by Universities/Institutes 15 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Products Glance 17 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Development by Companies 21 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Investigation by Universities/Institutes 27 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development 29 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment 93 Drug Profiles 110 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects 421 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products 428 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones 430 Appendix 443
List of Tables
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H2 2016 20 Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis, H2 2016 21 Number of Products under Development by Companies, H2 2016 22 Number of Products under Development by Companies, H2 2016 (Contd..1) 23 Number of Products under Development by Companies, H2 2016 (Contd..2) 24 Number of Products under Development by Companies, H2 2016 (Contd..3) 25 Number of Products under Development by Companies, H2 2016 (Contd..4) 26 Number of Products under Investigation by Universities/Institutes, H2 2016 28 Comparative Analysis by Late Stage Development, H2 2016 29 Comparative Analysis by Clinical Stage Development, H2 2016 30 Comparative Analysis by Early Stage Development, H2 2016 31 Comparative Analysis by Unknown Stage Development, H2 2016 32 Products under Development by Companies, H2 2016 33 Products under Development by Companies, H2 2016 (Contd..1) 34 Products under Development by Companies, H2 2016 (Contd..2) 35 Products under Development by Companies, H2 2016 (Contd..3) 36 Products under Development by Companies, H2 2016 (Contd..4) 37 Products under Development by Companies, H2 2016 (Contd..5) 38 Products under Investigation by Universities/Institutes, H2 2016 39 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 40 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AbbVie Inc, H2 2016 41 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Altor BioScience Corp, H2 2016 42 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by arGEN-X BV, H2 2016 43 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H2 2016 44 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Array BioPharma Inc, H2 2016 45 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016 46 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 47 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Atara Biotherapeutics Inc, H2 2016 48 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 49 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bio-Path Holdings Inc, H2 2016 50 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Biogenomics Limited, H2 2016 51 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioLineRx Ltd, H2 2016 52 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioSight Ltd, H2 2016 53 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Boston Biomedical Inc, H2 2016 54 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bristol-Myers Squibb Company, H2 2016 55 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cantargia AB, H2 2016 56 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celgene Corp, H2 2016 57 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cellectar Biosciences Inc, H2 2016 58 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cielo Therapeutics Inc, H2 2016 59 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Constellation Pharmaceuticals Inc, H2 2016 60 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 61 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 62 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 63 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Eisai Co Ltd, H2 2016 64 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by EpiZyme Inc, H2 2016 65 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 66 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Galena Biopharma Inc, H2 2016 67 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Gamida Cell Ltd, H2 2016 68 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlycoMimetics Inc, H2 2016 69 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by HEC Pharm Co., Ltd., H2 2016 70 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hovione FarmaCiencia SA, H2 2016 71 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hybrigenics SA, H2 2016 72 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ilyang Pharmaceutical Co Ltd, H2 2016 73 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Incyte Corp, H2 2016 74 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Co Ltd, H2 2016 75 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Johnson & Johnson, H2 2016 76 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Juno Therapeutics Inc, H2 2016 77 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by JW Pharmaceutical Corp, H2 2016 78 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Karyopharm Therapeutics Inc, H2 2016 79 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016 80 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Mesoblast Ltd, H2 2016 81 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Natco Pharma Ltd, H2 2016 82 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Novartis AG, H2 2016 83 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by OncoTherapy Science Inc, H2 2016 84 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 85 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Oribase Pharma, H2 2016 86 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Panther Biotechnology, Inc., H2 2016 87 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pfizer Inc, H2 2016 88 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pharma Mar SA, H2 2016 89 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by PharmaEssentia Corp, H2 2016 90 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Sellas Inc, H2 2016 91 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Selvita SA, H2 2016 92 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Shenogen Pharma Group Ltd, H2 2016 93 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Shire Plc, H2 2016 94 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by SignalChem Lifesciences Corp, H2 2016 95 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Stemline Therapeutics Inc, H2 2016 96 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 97 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Syndax Pharmaceuticals Inc, H2 2016 98 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 99 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Targazyme Inc, H2 2016 100 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 101 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 102 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Tragara Pharmaceuticals Inc, H2 2016 103 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by VioQuest Pharmaceuticals Inc, H2 2016 104 Assessment by Monotherapy Products, H2 2016 105 Assessment by Combination Products, H2 2016 106 Number of Products by Stage and Target, H2 2016 108 Number of Products by Stage and Mechanism of Action, H2 2016 113 Number of Products by Stage and Route of Administration, H2 2016 119 Number of Products by Stage and Molecule Type, H2 2016 121 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H2 2016 433 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..1), H2 2016 434 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..2), H2 2016 435 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..3), H2 2016 436 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..4), H2 2016 437 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..5), H2 2016 438 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..6), H2 2016 439 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, H2 2016 440 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products (Contd..1), H2 2016 441
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
